The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CFTR modulators: transformative therapies for cystic fibrosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dwight and Marshall previously reported a 61% reduction in PEx in the CFFPR among people with CF aged ≥12 years following ELX/TEZ/IVA approval, but before the onset of the pandemic [22]”
From Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study (2023) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
Research works printed but not linked: 3
- 10.1016/S2213-2600(18)30202-9 · DOI
- 10.1164/rccm.201503-0578OC · DOI · Paper page
- 10.1016/S2213-2600(16)30427-1 · DOI · Paper page
Cited by
Sorted by citations
Bower, J. K., Volkova, N., Ahluwalia, N., Sahota, G., Xuan, F., Chin, A., Weinstock, T. G., Ostrenga, J., & Elbert, A. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.03.002 · Cited by 140
Metadata
- Authors
- Dwight, M., & Marshall, B.
- Affiliations
- Cystic Fibrosis Foundation, Bethesda, MD.
- Venue
- Journal of Managed Care & Specialty Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2021-02
- Volume
- 27
- Issue
- 2
- Pages
- 281-284
- ISSN
- 2376-0540
- 2376-1032
- Cited by
- 9
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CFTR modulators: transformative therapies for cystic fibrosis. https://app.cochat.ai/papers/10.18553/jmcp.2021.27.2.281
- The paper
- Dwight, M., & Marshall, B. (2021). CFTR modulators: transformative therapies for cystic fibrosis. Journal of Managed Care & Specialty Pharmacy. https://doi.org/10.18553/jmcp.2021.27.2.281
